{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1010000781983167626.json","@type":"Article","resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"ja","@value":"Population Pharmacolinetic and Pharmacodynamic Analysis of a Class IC Antiarrhythmic, Pilsicainide, in Patients With Cardiac Arrhythmias."}],"publication":{"prism:publicationName":[{"@language":"ja","@value":"J Clin Pharmacol. 46(10"}],"prism:publicationDate":"2006","prism:startingPage":"59","prism:endingPage":"68"},"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781983167616","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"18590155"},{"@type":"JGN","@value":"JP18590155"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18590155/"}],"notation":[{"@language":"ja","@value":"新規バイオマーカーに基づく免疫抑制剤の用法用量の個別最適化"},{"@language":"en","@value":"Individualization of dosage for immunosuppressive drugs based on new biomarkers"}]}],"dataSourceIdentifier":[{"@type":"KAKEN","@value":"PRODUCT-19330945"}]}